Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- DSP’s US Subsidiary Sunovion Announces FDA Acceptance of NDA Resubmission for Epilepsy Treatment Stedesa
March 1, 2013
- Takeda to Develop New Compounds for Autoimmune Diseases Jointly with Resolve Therapeutics of US
March 1, 2013
- Taiho Files for Novel Anticancer Agent TAS-102 in Japan
March 1, 2013
- BMKK, Pfizer Japan Launch, Copromote Anti-Xa Agent Eliquis
March 1, 2013
- Shionogi Receives FDA Approval for Dyspareunia Treatment, Plans its Launch in June
February 28, 2013
- Gilenya Achieved Blockbuster Status in 2012; Canagliflozin Will Be Next: Pres. Tsuchiya of MTPC
February 28, 2013
- MTPC Files for Expanded Combination-Use Indication for DPP-4 Inhibitor Tenelia
February 28, 2013
- GSK Launches Anti-Malaria Drug Malarone in Japan
February 27, 2013
- Takeda Recalling Renal Anemia Drug Omontys in US after Death Reports
February 26, 2013
- Combined Sales of Januvia and Glactiv Break 110 Billion Yen in 2012: IMS Japan
February 26, 2013
- Janssen Files World’s 1st Application for Hepatitis C Treatment Simeprevir in Japan
February 26, 2013
- 3-Drug H. pylori Eradication Therapy Receives Additional Indication for H. pylori Gastritis
February 25, 2013
- Zeria to Launch Hypophosphatemia Treatment Phosribbon Combination Granules on March 4
February 25, 2013
- MTPC Calls for Proper Use of Telavic Following Reports of Serious Infections
February 25, 2013
- LEO Pharma of Denmark to Fully Enter Psoriasis Market in Japan in 2014
February 22, 2013
- Lotriga, Equa, Aimix Most Promoted Products in GP, HP Markets in January: Rep Track Survey
February 22, 2013
- Astellas Files for Additional Indication for Dormicum Based on Data from Public Domain
February 22, 2013
- Shionogi Settles Lawsuit over Royalties Payment with US Firm InterMune
February 22, 2013
- Shire Appoints Steve Engen as Representative Director of Japanese Subsidiary
February 22, 2013
- Actelion Receives Approval for Generic Version of Flolan
February 22, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…